Company Description
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action.
The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer.
The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer.
It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210.
The company is headquartered in Princeton, New Jersey.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Pankaj Mohan |
Contact Details
Address: 100 Overlook Center, Suite 102 Princeton, New Jersey 08540 United States | |
| Phone | 609 375 2227 |
| Website | sonnetbio.com |
Stock Details
| Ticker Symbol | SONN |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001106838 |
| CUSIP Number | 83548R105 |
| ISIN Number | US83548R3030 |
| Employer ID | 52-2102141 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pankaj Mohan Ph.D. | Founder, Chairman, Chief Executive Officer and President |
| Dr. John K. Cini Ph.D. | Chief Scientific Officer and Co-Founder |
| Jay Cross | Chief Financial Officer |
| Dr. Gael Hedou Ph.D. | Chief Operating Officer |
| Susan Dexter | Chief Technical Officer |
| Dr. Richard T. Kenney FACP, M.D. | Chief Medical Officer |
| Manuel Dafonseca | Head of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 8, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 424B4 | Prospectus |
| Nov 6, 2024 | EFFECT | Notice of Effectiveness |
| Nov 6, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Nov 6, 2024 | 8-K | Current Report |
| Nov 4, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Oct 28, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Oct 17, 2024 | 8-K | Current Report |
| Oct 9, 2024 | 8-K | Current Report |
| Sep 30, 2024 | 8-K | Current Report |